SAM
MRNA icon

Smartleaf Asset Management’s Moderna MRNA Stock Holding History

Smartleaf Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.3K Buy
960
+134
+16% +$6.25K ﹤0.01% 1498
2025
Q4 		$25.1K Sell
826
-77
-9% -$2.09K ﹤0.01% 1907
2025
Q3 		$22.9K Buy
903
+719
+391% +$20.1K ﹤0.01% 1759
2025
Q2 		$5K Sell
184
-328
-64% -$8.64K ﹤0.01% 2050
2025
Q1 		$15.9K Sell
512
-51
-9% -$1.81K ﹤0.01% 1727
2024
Q4 		$22.2K Sell
563
-476
-46% -$22.8K ﹤0.01% 1591
2024
Q3 		$68.3K Buy
1,039
+460
+79% +$42.2K 0.01% 814
2024
Q2 		$70.2K Sell
579
-34
-6% -$4.3K 0.01% 660
2024
Q1 		$67.8K Buy
613
+560
+1,057% +$56.4K 0.01% 608
2023
Q4 		$5.23K Buy
+53
New +$4.46K ﹤0.01% 860

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Smartleaf Asset Management's MRNA Position: Q1 2026 in Review

Smartleaf Asset Management increased its Moderna (MRNA) stake by 16% in Q1 2026, buying an estimated $6.25K and bringing the position to 960 shares worth $46.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1498.

Smartleaf Asset Management first reported a position in MRNA in Q4 2023 and has held it in 10 quarters since. The position peaked at $70.2K in Q2 2024. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Smartleaf Asset Management held 960 shares of Moderna worth $46.3K as of Q1 2026.
  • Smartleaf Asset Management bought 134 Moderna shares in Q1 2026, an estimated $6.25K.
  • Moderna made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #1498 holding.
  • Smartleaf Asset Management first reported a position in Moderna in Q4 2023 and has held it in 10 quarters since.
  • Smartleaf Asset Management's Moderna position peaked at $70.2K in Q2 2024.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.